RIPK2 inhibitors for disease therapy: Current status and perspectives

Area of Science:

• Molecular Biology
• Immunology
• Biochemistry

Background:

• Receptor-interacting protein kinase 2 (RIPK2) is a cytoplasmic protein widely expressed in human tissues.
• It functions as a dual-specificity kinase and adapter molecule in innate and adaptive immunity.
• RIPK2 plays roles in Toll-like receptor (TLR) and nucleotide-binding oligomerization domain (NOD) signaling pathways.

Purpose of the Study:

• To review the molecular structure and biological functions of RIPK2.
• To examine the correlation between RIPK2 and human diseases.
• To focus on small molecule inhibitors of RIPK2, their structure-activity relationships, and therapeutic potential.

Main Methods:

• Literature review of RIPK2 structure, function, and disease associations.
• Analysis of structure-activity relationships of RIPK2 inhibitors.
• Evaluation of therapeutic potential in disease contexts.

Main Results:

• RIPK2 interacts with tumor necrosis factor receptor (TNFR) and is crucial in immune signaling.
• Dysregulation of RIPK2 is implicated in inflammatory responses, autoimmune diseases, and tumors.
• Small molecule inhibitors targeting RIPK2 show therapeutic promise.

Conclusions:

• RIPK2 is a significant molecular target for therapeutic intervention in various diseases.
• Understanding RIPK2's structure-activity relationships is key to developing effective small molecule inhibitors.
• RIPK2-targeted therapies hold potential for treating inflammatory conditions, autoimmune disorders, and cancers.